28-May-2021 | Facts and Factors
As per the market research report published by Facts and Factors, the global C1 inhibitors market was valued at USD 3,300 Million in 2019. This market is further expected to generate revenue of around USD 9,800 Million by end of 2026, growing at a CAGR of around 18.6% between 2021 and 2026.
C1 inhibitors are a type of protease inhibitor that belongs to a protein-based ingredient called serpin. They are also called C1 esterase inhibitors; however, unlike other members of the protein tree, they contain both the domains C-terminal and N-terminal. These inhibitors basically help lower the self-consciousness of the complement system to prevent any type of damage as well as to retain the functionality. It is an FXIIa inhibitor that can help coagulate blood, produce kinins or fibrinolysis, and also activate the complement system.
Rising prevalence of hereditary angioedema (HAE) diseases and the preferred mode of treatment for prophylactic-based disorders are likely to drive the growth of the market during the forecast period. Additionally, certain impactful studies have indicated that the use of C1 inhibitors will further drive the growth of the market. Furthermore, the growing awareness regarding the effectiveness of C1 inhibitors and their ability in preventing heart attacks will boost the market expansion. C1 inhibitors use as a short-term treatment for prophylactic diseases propel the demand for this product across the globe. But, a few of the reasons including misdiagnosis, expensive medicines, and longer time for reimbursements are projected to restrain the market growth.
Top Market Players
The key participants of the global C1 inhibitors market are Viropharma Biologics, Inc., Ionis Pharmaceuticals, Inc., iBio, Inc., Sanquin, and BioCryst Pharmaceuticals, among others.
Market Dynamics
The C1 inhibitor market can be divided into human-derived and recombinantly derived on the basis of the source. The human-derived C1 inhibitor segment can be further broken down into CINRYZE, Berinert, and HAEGARDA while the recombinant derived segment can be further broken down into Ruconest
The C1 inhibitors market can be broken down into intravenous and subcutaneous on the basis of mode of administration. Growing adoption of the subcutaneous route of administration by doctors and improving availability of Ruconest further fuel the C1 inhibitor market. Thus, the subcutaneous mode of administration is likely to exhibit maximum market revenue.
North America Is Expected To Flourish During The Forecast Period
North America is expected to recoup the largest market share during the forecast period in terms of global revenue collection. Factors pertaining to the rise of the market in the region can be contributed to increased awareness about HAE treatment protocols and widened support for reimbursement support from governmental agencies. Additionally, the well-established healthcare infrastructure and improved healthcare access will also help boost the global C1 inhibitors market in this region.
Browse the full “C1 Inhibitors Market By Source (Human Derived & Recombinant Derived C1 Inhibitors), By Mode of Administration (Intravenous & Subcutaneous), By End-User (Hospitals & Pharmacies), and By Regions - Global Industry Perspective, Comprehensive Analysis, and Forecast, 2020 – 2026” report at https://www.fnfresearch.com/c1-inhibitors-market
Report Scope
Report Attribute |
Details |
Market Size in 2020 |
USD 3,300 Million |
Projected Market Size in 2026 |
USD 9,800 Million |
CAGR Growth Rate |
18.6% CAGR |
Base Year |
2020 |
Forecast Years |
2021-2026 |
Key Market Players |
Shire, CSL Behring, Lev Pharmaceuticals, Pharming Group, Salix Pharmaceuticals, Viropharma Biologics, Inc., Ionis Pharmaceuticals, Inc., iBio, Inc., Sanquin, and BioCryst Pharmaceuticals., among others.
|
Key Segment |
By Source, By Mode of Administration, By End-User, and By Region |
Major Regions Covered |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
Purchase Options |
Request customized purchase options to meet your research needs. Explore purchase options |
The global C1 Inhibitors Market can be segmented into:
Global C1 Inhibitors Market: By Source Segment Analysis
- Human Derived C1 Inhibitors
- CINRYZE
- Berinert
- HAEGARDA
- Recombinant Derived C1 Inhibitors
Global C1 Inhibitors Market: By Mode of Administration Segment Analysis
Global C1 Inhibitors Market: By End-User Segment Analysis
Global C1 Inhibitors Market: By Regional Segment Analysis
- North America
- Europe
- UK
- France
- Germany
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Southeast Asia
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East and Africa
- GCC Countries
- South Africa
- Rest of MEA
About Us:
Facts & Factors is a leading market research organization offering industry expertise and scrupulous consulting services to clients for their business development. The reports and services offered by Facts and Factors are used by prestigious academic institutions, start-ups, and companies globally to measure and understand the changing international and regional business backgrounds. Our client’s/customer’s conviction on our solutions and services has pushed us in delivering always the best. Our advanced research solutions have helped them in appropriate decision-making and guidance for strategies to expand their business.
Contact Us:
Facts & Factors
A 2108, Sargam,
Nanded City,
Sinhagad Road,
Pune 411041, India
USA: +1-347-989-3985
Email: [email protected]
Web: https://www.fnfresearch.com
